Clinical trials: Non-steroid Anti-inflammatory Drugs
Dermatitis, Atopic
Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream
Welichem Biotech has developed a small molecule drug candidate, WBI-1001, that selectively targets the pathogenic features of inflammatory skin diseases, including atopic dermatitis (a form of eczema).The purpose of this clinical…
- Trial name
- NCT01098734
- Testing
- WBI-1001
- Where
- 5 sites in Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Psoriasis
A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin.
- Trial name
- 134993 (NCT01098721)
- Testing
- WBI-1001
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Rheumatoid Arthritis, Osteoarthritis
Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy
The purpose of this study is to evaluate the efficacy of eupatilin on the prevention of gastroenteropathy in patients with NSAIDs and low dose steroid by comparing with rebamipide.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, Other Musculoskeletal Disorder
- Trial name
- CEERS (NCT04885751)
- Testing
- Eupatilin, Rebamipide
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Seoul National University Boramae Hospital
Hyperemia, Intraocular Pressure
Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes
PG-analogues induce hyperemia as one of side effects in addition to IOP reduction. IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.
- Trial name
- ENTICHIR (NCT02136589)
- Testing
- dicrofenac and travoprost
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tokyo University